Time Trend Analysis of Primary Tumor Resection for Stage IV Colorectal Cancer Less Surgery, Improved Survival

被引:108
作者
Hu, Chung-Yuan [1 ]
Bailey, Christina E. [1 ]
You, Y. Nancy [1 ]
Skibber, John M. [1 ]
Rodriguez-Bigas, Miguel A. [1 ]
Feig, Barry W. [1 ]
Chang, George J. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
COLON-CANCER; IRINOTECAN; TRIAL; FLUOROURACIL; CHEMOTHERAPY; OXALIPLATIN; BEVACIZUMAB; LEUCOVORIN; MANAGEMENT; CETUXIMAB;
D O I
10.1001/jamasurg.2014.2253
中图分类号
R61 [外科手术学];
学科分类号
摘要
IMPORTANCE With the advent of effective modern chemotherapeutic and biologic agents, primary tumor resection for patients with stage IV colorectal cancer (CRC) may not be routinely necessary. OBJECTIVE To evaluate the secular patterns of primary tumor resection use in stage IV CRC in the United States. DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort study using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results CRC registry. Demographic and clinical factors were compared for 64 157 patients diagnosed with stage IV colon or rectal cancer from January 1, 1988, through December 31, 2010, who had undergone primary tumor resection and those who had not. Rates of primary tumor resection and median relative survival were calculated for each year. Joinpoint regression analysis was used to determine when a significant change in trend in the primary tumor resection rate had occurred. Logistic regression analysis was used to assess factors associated with primary tumor resection. MAIN OUTCOMES AND MEASURES Difference in primary tumor resection rates over time. RESULTS Of the 64 157 patients with stage IV CRC, 43 273 (67.4%) had undergone primary tumor resection. The annual rate of primary tumor resection decreased from 74.5% in 1988 to 57.4% in 2010 (P <.001), and a significant annual percentage change occurred between 1998-2001 and 2001-2010 (-0.41% vs -2.39%; P <.001). Factors associated with primary tumor resection were age younger than 50 years, female sex, being married, higher tumor grade, and presence of colon tumors. Median relative survival rate improved from 8.6% in 1988 to 17.8% in 2009 (P <.001); the annual percentage change was 2.18% in 1988-2001 and 5.43% in 1996-2009 (P <.001). CONCLUSIONS AND RELEVANCE The majority of patients with stage IV CRC had undergone primary tumor resection but, beginning in 2001, a trend toward fewer primary tumor resections was seen. Despite the decreasing primary tumor resection rate, patient survival rates improved. However, primary tumor resection may still be overused, and current treatment practices lag behind evidence-based treatment guidelines.
引用
收藏
页码:245 / 251
页数:7
相关论文
共 28 条
[1]   Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases [J].
Adam, R .
ANNALS OF ONCOLOGY, 2003, 14 :13-16
[2]  
[Anonymous], SEER CANCER STATISTI
[3]   Clinical Practice Guidelines in Oncology [J].
Benson, Al B., III ;
Arnoletti, J. Pablo ;
Bekaii-Saab, Tanios ;
Chan, Emily ;
Chen, Yi-Jen ;
Choti, Michael A. ;
Cooper, Harry S. ;
Dilawari, Raza A. ;
Engstrom, Paul F. ;
Enzinger, Peter C. ;
Fleshman, James W., Jr. ;
Fuchs, Charles S. ;
Grem, Jean L. ;
Knol, James A. ;
Leong, Lucille A. ;
Lin, Edward ;
May, Kilian Salerno ;
Mulcahy, Mary F. ;
Murphy, Kate ;
Rohren, Eric ;
Ryan, David P. ;
Saltz, Leonard ;
Sharma, Sunil ;
Shibata, David ;
Skibber, John M. ;
Small, William, Jr. ;
Sofocleous, Constantinos T. ;
Venook, Alan P. ;
Willett, Christopher .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (11) :1238-1290
[4]   Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable Stage IV colorectal cancer [J].
Cirocchi, Roberto ;
Trastulli, Stefano ;
Abraha, Iosief ;
Vettoretto, Nereo ;
Boselli, Carlo ;
Montedori, Alessandro ;
Parisi, Amilcare ;
Noya, Giuseppe ;
Platell, Cameron .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (08)
[5]   Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: An analysis of surveillance, epidemiology, and end results data, 1988 to 2000 [J].
Cook, AD ;
Single, R ;
McCahill, LE .
ANNALS OF SURGICAL ONCOLOGY, 2005, 12 (08) :637-645
[6]   Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer [J].
Di Nicolantonio, Federica ;
Martini, Miriam ;
Molinari, Francesca ;
Sartore-Bianchi, Andrea ;
Arena, Sabrina ;
Saletti, Piercarlo ;
De Dosso, Sara ;
Mazzucchelli, Luca ;
Frattini, Milo ;
Siena, Salvatore ;
Bardelli, Alberto .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) :5705-5712
[7]   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342
[8]   K-ras mutations and benefit from cetuximab in advanced colorectal cancer [J].
Karapetis, Christos S. ;
Khambata-Ford, Shirin ;
Jonker, Derek J. ;
O'Callaghan, Chris J. ;
Tu, Dongsheng ;
Tebbutt, Niall C. ;
Simes, R. John ;
Chalchal, Haji ;
Shapiro, Jeremy D. ;
Robitaille, Sonia ;
Price, Timothy J. ;
Shepherd, Lois ;
Au, Heather-Jane ;
Langer, Christiane ;
Moore, Malcolm J. ;
Zalcberg, John R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (17) :1757-1765
[9]   Primary Colectomy in Patients With Stage IV Colon Cancer and Unresectable Distant Metastases Improves Overall Survival: Results of a Multicentric Study [J].
Karoui, Mehdi ;
Roudot-Thoraval, Francoise ;
Mesli, Farida ;
Mitry, Emmanuel ;
Aparicio, Thomas ;
DesGuetz, Gaetan ;
Louvet, Christophe ;
Landi, Bruno ;
Tiret, Emmanuel ;
Sobhani, Iradj .
DISEASES OF THE COLON & RECTUM, 2011, 54 (08) :930-938
[10]  
KEENEY S, 1993, J BIOL CHEM, V268, P21293